Objective： To analyze the results and introduce the experiences of transhiatal esophagectomy in combined with different synthetic therapy. Methods： Seventy-one patients with esophageal carcinoma, median age was 62, ...Objective： To analyze the results and introduce the experiences of transhiatal esophagectomy in combined with different synthetic therapy. Methods： Seventy-one patients with esophageal carcinoma, median age was 62, 40 of stage Ⅰ, 26 of Ⅱa, 4 of stage Ⅱb, 1 of stage Ⅳ, were treated with transhiatal esophagectomy. 9 and 17 patients were treated with preoperative radiotherapy （4000 cGy） and postoperative adjuvant radiotherapy （6000 cGy） respectively; 5 patients were treated with preoperative chemotherapy. Results： The postoperative 1, 3 and 5 years survival rates were 100%, 91.43%, and 86.21% for stage Ⅰ; 92%, 83.33%, and 57.14% for stage Ⅱa; 75%, 50%, and 50% for stage Ⅱb; 100%, 0, and 0 for stag Ⅳ and 95.71%, 86.89%, and 71.70% as a whole, respectively. The incidence of complications was 12.68%. Conclusion： Transhiatal esophagectomy combined with chemotherapy or radiotherapy may be beneficial to patients with esophageal carcinoma at stage Ⅱa or earlier who can＇t tolerate or need not be treated by transthoracic esophagectomy.展开更多
文摘Objective： To analyze the results and introduce the experiences of transhiatal esophagectomy in combined with different synthetic therapy. Methods： Seventy-one patients with esophageal carcinoma, median age was 62, 40 of stage Ⅰ, 26 of Ⅱa, 4 of stage Ⅱb, 1 of stage Ⅳ, were treated with transhiatal esophagectomy. 9 and 17 patients were treated with preoperative radiotherapy （4000 cGy） and postoperative adjuvant radiotherapy （6000 cGy） respectively; 5 patients were treated with preoperative chemotherapy. Results： The postoperative 1, 3 and 5 years survival rates were 100%, 91.43%, and 86.21% for stage Ⅰ; 92%, 83.33%, and 57.14% for stage Ⅱa; 75%, 50%, and 50% for stage Ⅱb; 100%, 0, and 0 for stag Ⅳ and 95.71%, 86.89%, and 71.70% as a whole, respectively. The incidence of complications was 12.68%. Conclusion： Transhiatal esophagectomy combined with chemotherapy or radiotherapy may be beneficial to patients with esophageal carcinoma at stage Ⅱa or earlier who can＇t tolerate or need not be treated by transthoracic esophagectomy.
